NCT06730360 Clinical and Radiographic Assessment of Photobiomodulated MTA Pulpotomy in Immature First Permanent Molars with Irreversible Pulpitis
| NCT ID | NCT06730360 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mansoura University |
| Condition | Dental Caries |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2024-10-10 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2024-10-10 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the effectiveness of photobiomodulation (PBM) in conjunction with mineral trioxide aggregate (MTA) pulpotomy for treating irreversible pulpitis in immature first permanent molars. PBM, also known as low-level laser therapy (LLLT), is used to enhance healing, reduce inflammation, and manage pain in young teeth. The randomized clinical trial involves 72 children aged 6-9 years, divided into two groups: one receiving MTA pulpotomy alone and the other receiving MTA pulpotomy with PBM. Clinical and radiographic outcomes will be assessed at intervals over 15 months. This research aims to determine the combined therapy's efficacy in improving pulp healing and reducing post-operative discomfort compared to MTA alone.
Eligibility Criteria
Inclusion Criteria: * Children aged 6 to 9 years. * Non-contributory medical history (healthy otherwise). * Presence of carious first permanent molars with the following characteristics: * Deep caries extending to ≥2/3 of dentin. * Positive response to cold testing. * Clinical diagnosis of irreversible pulpitis (moderate or severe), with or without periapical periodontitis. * Restorable tooth. * Probing pocket depth and mobility within normal limits. * No signs of pulpal necrosis, including sinus tract or swelling. Exclusion Criteria: * Insufficient bleeding after pulp exposure (indicating necrotic or partially necrotic pulp). * Presence of systemic or medical conditions that may contraindicate participation. * Teeth with unrestorable structure. * Teeth showing signs of pulpal necrosis, such as the presence of a sinus tract or swelling.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06730360 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 9 Years, studying Dental Caries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06730360 currently recruiting?
Yes, NCT06730360 is actively recruiting participants. Contact the research team at petersamir@mans.edu.eg for enrollment information.
Where is the NCT06730360 trial being conducted?
This trial is being conducted at Al Mansurah, Egypt.
Who is sponsoring the NCT06730360 clinical trial?
NCT06730360 is sponsored by Mansoura University. The trial plans to enroll 72 participants.